Get the Stockscreener App
56.23
2.82%
1.54
After Hours:
56.11
-0.12
-0.21%
Royalty Pharma Plc stock is traded at $56.23, with a volume of 6.97M.
It is up +2.82% in the last 24 hours and up +4.40% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$54.69
Open:
$54.6
24h Volume:
6.97M
Relative Volume:
1.94
Market Cap:
$24.93B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
29.45
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+6.17%
1M Performance:
+4.40%
6M Performance:
+43.37%
1Y Performance:
+59.43%
1-Day Range:
$54.60
$56.29
1-Week Range:
$52.89
$56.29
52-Week Range:
$34.08
$56.50
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
56.23 | 24.93B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC $RPRX Shares Sold by Goodman Advisory Group LLC - MarketBeat
Enterprise value to EBITDA forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Price to earnings forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to EBITDA forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Insider Sell Alert: Marshall Urist Sells Shares of Royalty Pharm - GuruFocus
Royalty Pharma EVP Hite sells $8.16m in shares - Investing.com UK
Form 4 Royalty Pharma Plc For: 25 June By Investing.com - Investing.com South Africa
Royalty Pharma EVP Hite sells $8.16m in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares - MarketBeat
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan - Stock Titan
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX) - TradingView
RPRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 24 June By Investing.com - Investing.com Australia
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX) - Stock Titan
Kirr Marbach & Co. LLC IN Acquires Shares of 237,895 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 144 Royalty Pharma PLC For: 23 June By Investing.com - Investing.com South Africa
[144] Royalty Pharma plc SEC Filing - Stock Titan
Look Beyond Market Euphoria After 3 FCF ETFs Rebalanced - ETF Database
Royalty Pharma plc (RPRX) Stock Analysis: Exploring an 11.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Three “Forever Stocks” for the AI Age - InvestorPlace
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dorsey Asset Management LLC Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Delta Global Management LP Acquires Shares of 44,314 Royalty Pharma PLC $RPRX - MarketBeat
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report - Stock Titan
L2 Asset Management LLC Has $5.63 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 31,091 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Bought by Entropy Technologies LP - MarketBeat
Fieldview Capital Management LLC Invests $3.74 Million in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Raises Stake in Royalty Pharma PLC $RPRX - MarketBeat
Rhenman & Partners Asset Management AB Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
This Royalty Pharma Insider Reduced Their Stake By 10% - Yahoo Finance
Heartland Advisors Inc. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 23 '26 |
Sale |
54.40 |
150,000 |
8,159,277 |
559,399 |
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):